<DOC>
	<DOCNO>NCT01721798</DOCNO>
	<brief_summary>This study inform international medical guideline whether Levonorgestrel intrauterine device ( LNG IUD ) , highly effective long-acting reversible contraceptive method , safe acceptable compare copper intrauterine device ( C-IUD ) HIV-positive woman Cape Town , South Africa . If LNG IUD find safe acceptable , introduction method HIV positive woman develop country could significantly reduce unplanned pregnancy mother-to-child transmission HIV , confer non-contraceptive benefit HIV-positive woman Sub-Saharan Africa .</brief_summary>
	<brief_title>Comparison Two IUDs Among Cape Town HIV-positive Women</brief_title>
	<detailed_description>Design : Single site , double-blind , randomize control trial Population : HIV-positive South African woman age 18 40 year Study size : 288 woman Study intervention : Levonorgestrel intrauterine device ( LNG IUD ) copper T-380 intrauterine device ( C-IUD ) Duration &amp; Follow-up : Approximately 48 month total . Recruitment take approximately 24 month . After enrollment , participant follow 24 month . Primary Objectives : To compare LNG IUD safety safety C-IUD respect genital HIV shedding , surrogate potential HIV transmission , overall presence absence ART . Secondary Objectives : 1 ) To compare LNG IUD safety safety C-IUD respect HIV progression measure change plasma viral load ( VL ) 6 month two pre-ART study arm . 2 ) To explore LNG IUD safety respect non-HIV related outcome , include hemoglobin change , incidence sexually-transmitted infection ( STIs ) pelvic inflammatory disease ( PID ) . 3 ) To measure LNG IUD acceptability device continuation measure LNG IUD compare C-IUD . 4 ) To compare three genital tract sample method determine provide optimal recovery HIV RNA immune mediator series three visit . Primary Endpoints : Change detection quantity HIV RNA genital VL measure study arm baseline 6 month , 24 month follow IUD insertion . Secondary Endpoints : 1 ) Measures HIV disease progression , include CD4 change , time ART initiation , mean plasma VL change baseline 6 24 month among pre-ART woman . 2 ) Hemoglobin change incidence STIs PID participant 24 month . 3 ) IUD continuation expulsion rate study arm compare different IUDs 24-month period acceptability measure quantitative qualitative method . 4 ) Comparison female genital tract sample method recovery HIV RNA measure VL immune mediator ( e.g . cytokine ) . Study Site : Gugulethu Community Health Centre ( GCHC ) , Cape Town , South Africa</detailed_description>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Inclusion Criteria Willing able provide write informed consent ( IC ) screen participate trial Interested willing use IUD family planning method . Between 18 40 year age ( inclusive ) : This age range include woman year greatest fertility 18 age majority research consent South Africa . Willing participate aspect study comply study procedures visit , 24 month , include : Be randomize Adhere followup schedule willing contact site staff study visit ( phone and/or person ) Provide contact/locator information Agree site staff review clinic chart confirm HIV status Has document HIV infection For preART entrant : ARTineligible screening , base current South African ART guideline Be least 6 month postdelivery pregnant desire pregnancy next 30 month . For ARTusing entrant : ARTuse demonstrate clinical record reflect laboratory measure consistent ART use evidence viral suppression ( plasma VL &lt; 1000 copies/mL ) recent VL measure . Be least 6 week postdelivery pregnant desire pregnancy next 30 month . Intending residence Cape Town area next 30 month No document known history infertility sterilization No gross evidence cervical neoplasia examination No prior history ectopic pregnancy No history suspect hormonallydependent neoplasm undiagnosed abnormal vaginal bleeding Local language fluency comprehension Not participate clinical trial biomedical intervention Have condition , base opinion Site PI , would preclude provision inform consent , make participation study unsafe , complicate interpretation data .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonization</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU International unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>Âµg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
</DOC>